standard-of-care options, and no single standardof-care regimen is superior in the treatment of advanced nsclc 7-10 . Thus, physicians rely on numerous factors to optimize treatment strategies, including histology, age, performance status, cost, tolerability, and convenience. The combination of a platinum agent with a taxane-either solvent-based (sb) paclitaxel (Taxol: Bristol-Myers Squibb, Princeton, NJ, U.S.A.) or docetaxel (Taxotere: SanofiAventis, Bridgewater, NJ, U.S.A.)-has a proven efficacy and safety profile in advanced nsclc 6 . The sb-paclitaxel-carboplatin regimen is among those most commonly used for the first-line treatment of advanced nsclc in the United States 11 .
INTRODUCTION
Non-small-cell lung cancer (nsclc) is a heterogeneous disease with multiple subtypes, including squamous cell carcinoma (scc), which accounts for 20%-30% of all nsclcs 1,2 . A large number of patients with nsclc are elderly, and 30% or more have a poor Eastern Cooperative Oncology Group (ecog) performance status (≥2) 1, 3, 4 . Outcomes for patients with advanced nsclc remain poor, with the 5-year survival rate being less than 4% 1 . The goals of treating advanced nsclc are therefore to prolong survival and to palliate symptoms.
Platinum-based doublet regimens, the current standard of care for the treatment of advanced nsclc, yield a 1-year survival rate of 30%-40% and are superior to single-agent therapy 5, 6 . However, a plateau in efficacy has been reached with current 10 . The orrs in the docetaxel-cisplatin, docetaxel-carboplatin, and vinorelbine-cisplatin arms were 32%, 24%, and 25% respectively; the difference in response was significant only for docetaxel-cisplatin compared with vinorelbine-cisplatin (p = 0.029). Additionally, docetaxel-cisplatin was associated with improved survival compared with vinorelbine-cisplatin (median os: 11.3 months vs. 10.1 months, p = 0.044); however, docetaxel-carboplatin did not show a survival advantage over vinorelbine-cisplatin (median os: 9.4 months vs. 9.9 months, p = ns). The docetaxelplatinum arms were also associated with improved tolerability, resulting in fewer grades 3 and 4 adverse events (aes) than resulted with vinorelbine-cisplatin. Those findings were consistent with findings in other phase iii trials comparing docetaxel-platinum combinations with other chemotherapy regimens 8, 10, [19] [20] [21] . The most common grades 3 and 4 aes reported with docetaxel-platinum combinations were neutropenia, leucopenia, and nausea and vomiting 8, 10, [19] [20] [21] .
The relative clinical benefit of various taxaneplatinum regimens was evaluated in the landmark phase iii study ecog 1594, which compared the efficacy and safety of sb-paclitaxel plus cisplatin or carboplatin, docetaxel-cisplatin, and gemcitabinecisplatin 8 . Although no survival advantage was noted for any of the 4 arms, the rate of aes was lower with sb-paclitaxel-carboplatin than with the other regimens 8 . Based on those findings, the sb-paclitaxelcarboplatin regimen became the reference regimen for future phase iii studies.
The effect of the taxane schedule on outcomes and tolerability has also been evaluated in the setting of advanced nsclc. Although an every-3-weeks schedule is indicated for sb-paclitaxel in the treatment of advanced nsclc 23 , a lower incidence of myelosuppression and neuropathy has been reported with weekly regimens. Thus, the weekly schedule might allow for delivery of a higher dose intensity of paclitaxel with less toxicity. Additionally, lowdose sb-paclitaxel has demonstrated proapoptotic and antiangiogenic effects in vitro 24 . Evidence from several phase ii/iii trials comparing the every-3-weeks and weekly schedules of sb-paclitaxel and docetaxel have demonstrated no significant difference in orr or survival in patients with advanced nsclc 11,25-30 . In those studies, the weekly schedule of sb-paclitaxel resulted in a higher incidence of anemia, and the every-3-weeks schedule resulted in a higher incidence of neuropathy 11, 25, 29 . Similarly, no difference in outcomes was noted between the every-3-weeks and weekly schedules of docetaxel in the second-line setting in patients with advanced nsclc, but hematologic events were more common in the every-3-weeks arms, with the exception of anemia in one study [26] [27] [28] .
Taxanes in Combination with Other ThirdGeneration Chemotherapy Agents
The advent of newer therapies has opened up a greater number of options for patients. Accordingly, the efficacy and safety of taxanes in combination with other third-generation chemotherapy agents such as gemcitabine and vinorelbine have also been assessed [31] [32] [33] [34] [35] .
No difference in efficacy outcomes were reported in a phase iii trial comparing sb-paclitaxel-gemcitabine with sb-paclitaxel-vinorelbine in patients with advanced nsclc, but more patients in the vinorelbine arm than in the gemcitabine arm experienced severe leucopenia, neutropenia, and febrile neutropenia (p < 0.001) 32 . Similarly, no survival advantage has been reported in phase iii trials comparing gemcitabine-carboplatin, gemcitabine-sb-paclitaxel, and sb-paclitaxel-carboplatin as first-line treatment for patients with advanced nsclc 33,34 .
In general, the incidence of grades 3 and 4 aes was higher with gemcitabine-carboplatin than with other regimens, but sb-paclitaxel-containing regimens resulted in a higher incidence of grades 3 and 4 sensory neuropathy 34 .
Current evidence suggests that a taxane plus gemcitabine is as effective as taxane-platinum doublets in the first-line treatment of advanced nsclc. However, the ae profiles of taxane doublets vary by agent and should be considered when a first-line therapy is chosen. In general, a taxane plus gemcitabine can be considered when a platinum agent is contraindicated 6,31 .
Taxanes in Combination with Molecularly Targeted Agents
The addition of molecularly targeted agents to taxane-platinum regimens, including agents targeting the angiogenesis pathway or known mutations associated with advanced nsclc, has been evaluated in several studies [36] [37] [38] [39] [40] [41] . In a phase ii trial of patients with advanced nsclc, the addition of bevacizumab to sb-paclitaxel-carboplatin resulted in a median os of 17.7 months compared with 14.9 months with sb-paclitaxel-carboplatin alone 40 . Toxicity was greater overall with the addition of bevacizumab, and a greater number of life-threatening pulmonary hemorrhagic events was observed, especially in patients with scc. Thus, patients with scc were excluded from the subsequent phase iii ecog 4599 trial 37 . In that trial, the addition of bevacizumab to sb-paclitaxel-carboplatin significantly improved median os (12.3 months vs. 10.3 months with the chemotherapy alone, p = 0.003), but was associated with greater toxicity and a greater incidence of treatment-related deaths. Based on those results, bevacizumab was approved for patients with nonsquamous nsclc 42 . More recently, a large openlabel phase iii trial (PointBreak) evaluated the addition of bevacizumab to first-line sb-paclitaxel-carboplatin or pemetrexed-carboplatin with respect to survival outcomes in patients with advanced nonsquamous nsclc 43 . No significant difference in os was observed (median: 12.6 months in the pemetrexed arm vs. 13.4 months in the sb-paclitaxel arm; hr: 1.00; 95% ci: 0.86 to 1.16; p = 0.949), the primary endpoint of the study. However, a statistically significant improvement in progression-free survival (pfs) favouring the pemetrexed arm was noted (median pfs: 6.0 months vs. 5.6 months; hr: 0.83; 95% ci: 0.71 to 0.96; p = 0.012). The orr (34.1% vs. 33.0%) and the disease control rate (65.9% vs. 69.8%) were similar in the treatment arms. Patients whose disease did not progress after first-line treatment received maintenance therapy with pemetrexed-bevacizumab in the pemetrexed arm (n = 292); patients in the sb-paclitaxel arm received bevacizumab as a single agent (n = 298). In a prespecified noncomparative survival analysis of patients who received maintenance therapy in the pemetrexed and sb-paclitaxel arms, median os was 17.7 months and 15.7 months respectively, and median pfs was 8.6 months and 6.9 months respectively. Toxicity profiles in the two regimens differed, with significantly more (p ≤ 0.025) treatment-related grades 3 and 4 anemia (14.5% vs. 2.7%), thrombocytopenia (23.3% vs. 5.6%), and fatigue (10.9% vs. 5.0%) in the pemetrexed arm and significantly more grades 3 and 4 neutropenia (40.6% vs. 25.8%), febrile neutropenia (4.1% vs. 1.4%), sensory neuropathy (4.1% vs. 0%) and grades 1 and 2 alopecia (36.8% vs. 6.6%) in the sb-paclitaxel arm. Altogether, those findings demonstrate similar activity for pemetrexed and sb-paclitaxel when used in combination with carboplatin-bevacizumab in the first-line treatment of patients with advanced nonsquamous nsclc.
Results from trials of cetuximab (Erbitux: BristolMyers Squibb) in combination with taxane-carboplatin have been mixed 38, 39 . In the BMS099 trial, patients received sb-paclitaxel or docetaxel, both in combination with carboplatin, with or without cetuximab as first-line therapy 39 . The median pfs (primary endpoint) was similar for treatment with or without cetuximab (4.4 months vs. 4.2 months, p = ns). An improved orr was observed with cetuximab added to chemotherapy (26% vs. 17% with chemotherapy alone, p = 0.007). The median os for cetuximab plus chemotherapy was 9.7 months; it was 8.4 months with chemotherapy alone (p = ns). Treatment-related grades 3 and 4 aes occurred more often with cetuximab. In the swog (formerly the Southwest Oncology Group) S0342 study, in which patients received either first-line sb-paclitaxel-carboplatin with concurrent cetuximab and maintenance cetuximab afterward, or sequential sb-paclitaxel-carboplatin followed by cetuximab, the orrs were similar in the treatment arms (concurrent: 32%; sequential: 30%; p = ns), as were the median oss (concurrent: 10.9 months; sequential: 10.7 months; p = ns) 38 . Compared with sequential therapy, concurrent therapy was associated with significantly greater rates of grades 3 and 4 toxicities (p = 0.002).
The foregoing studies demonstrated that the taxane-platinum combination plus a targeted agent was efficacious in patients with advanced nonsquamous nsclc; however, the addition of targeted agents was associated with an increased risk of toxicity.
A New Taxane for the Treatment of NSCLC
The rationale for the development of nab-paclitaxel stemmed from the observation that although sbpaclitaxel is effective, the solvent used in the formulation (Kolliphor el, formerly known as Cremophor el) could lead to severe hypersensitivity reactions and peripheral neuropathy [44] [45] [46] . In addition, Kolliphor el can reduce the availability of paclitaxel to tumours by entrapping paclitaxel in micelles 46, 47 . Compared in preclinical models with sb-paclitaxel, nab-paclitaxel reached a mean maximum blood concentration of free paclitaxel that was higher by a factor of 10 and an intratumoural concentration that was 33% higher in patients with advanced or metastatic solid tumours 48, 49 . Enhanced transport across endothelial cell layers was also demonstrated for nab-paclitaxel compared with sb-paclitaxel 49 . Because of its unique albumin formulation, nab-paclitaxel can be administered safely at doses higher than are possible with sb-paclitaxel 13, 47 . Compared with sb-paclitaxel, nabpaclitaxel also requires a shorter infusion time 13, 23 . Furthermore, sb-paclitaxel requires premedication to prevent hypersensitivity reactions; because of its solvent-free formulation, nab-paclitaxel does not 13, 23 .
In several trials, nab-paclitaxel-carboplatin demonstrated antitumour activity 12, 50, 51 . A phase i/ii study of nab-paclitaxel-carboplatin identified the maximum tolerated dose of single-agent nab-paclitaxel as 125 mg/m 2 administered in the first 3 weeks of a 4-week cycle 51 . The median os was 11 months, the orr was 30%, and the most common treatment-related toxicities were grades 3 and 4 neutropenia and grade 3 leucopenia, sensory neuropathy, fatigue, diarrhea, and anemia. Patients who experienced grade 3 sensory neuropathy generally experienced improvement to grade 2 or less within 60 days. A subsequent dosefinding study revealed that nab-paclitaxel 100 mg/ m 2 weekly, plus every-3-weeks carboplatin, had a favourable efficacy and safety profile in patients with advanced nsclc 50 . The 100 mg/m 2 3-of-4-weeks regimen resulted in an orr of 48% and a median os of 11.3 months. Furthermore, compared with an every-3-weeks schedule of nab-paclitaxel, the former regimen was associated with a lower rate of grade 3 or greater aes and with significant reductions in the incidence of peripheral neuropathy, myalgia, arthralgia, and alopecia. Thus, the 100 mg/m 2 3-of-4-weeks dose and schedule was chosen for a phase iii trial. In the randomized registered trial comparing that schedule of nab-paclitaxel with an every-3-weeks sb-paclitaxel schedule (both with carboplatin), the nab-paclitaxel combination demonstrated a significantly higher orr (33% vs. 25%, p = 0.005), the primary endpoint of the study; a 0.5-month longer median pfs (6.3 months vs. 5.8 months; hr: 0.902; 95% ci: 0.767 to 1.060; p = 0.214); and a greater than 1-month-longer median os (12.1 months vs. 11.2 months; hr: 0.922; 95% ci: 0.797 to 1.066; p = 0.271) as first-line treatment for patients with advanced nsclc 12 . The nab-paclitaxel-carboplatin combination was associated with more thrombocytopenia and anemia, but with significantly less sensory neuropathy, neutropenia, arthralgia, and myalgia. Additionally, patients receiving nab-paclitaxelcarboplatin experienced a faster time to improvement in sensory neuropathy: median time to improvement from grade 3 or greater sensory neuropathy to grade 1 was 38 days for nab-paclitaxel-carboplatin and 104 days for sb-paclitaxel-carboplatin. Compared with sb-paclitaxel-carboplatin, nab-paclitaxel-carboplatin was also associated with statistically and clinically significant reductions in patient-reported neuropathy, neuropathic pain in the hands and feet, and hearing loss assessed using the Functional Assessment of Cancer Therapy-Taxane instrument 12,52 .
Taxanes and Histology
Targeted therapies including bevacizumab, cetuximab, and the thymidylate synthase inhibitor pemetrexed (Alimta: Eli Lilly and Company, Indianapolis, IN, U.S.A.) have demonstrated benefit in some patient populations, but the observed benefit has been mixed and often dictated by histology 37, [53] [54] [55] [56] [57] . Some patients with nonsquamous nsclc derive greater benefit from those agents than from the standard of care, whereas no benefit compared with chemotherapy might be observed for patients with scc 37,53,54 . Thus, treatment options for the latter patients are limited. Use of bevacizumab is limited to patients with nonsquamous histology 42 . Pemetrexed is also currently not indicated for scc because of a lack of efficacy 54, 58 , possibly related to higher expression of thymidylate synthase in scc tumours 59 . Furthermore, some nsclc tumours present with mixed histology (for example, adenosquamous) 55 ; other tumours might be poorly differentiated, potentially containing a heterogeneous population of cells 55, 60 . Until recently, histology was not generally considered when treatment decisions were made 5 . Few phase iii studies have assessed outcome by histology; however, subanalyses of such trials are beginning to surface in light of histology's growing importance (Table ii Recently, a phase iii trial conducted by Treat and colleagues in patients with advanced nsclc treated with gemcitabine-carboplatin, gemcitabine-sbpaclitaxel, or sb-paclitaxel-carboplatin was retrospectively analyzed 33, 34 . No difference in orr was noted for patients with nonsquamous histology, but compared with gemcitabine-carboplatin, sb-paclitaxel-carboplatin was associated with a significantly greater orr in patients with scc (46% vs. 25%, p = 0.02) 33 . Across treatment groups, no significant differences by histology were noted with regard to os or time to progression. Additionally, no significant differences were noted in grades 3 and 4 aes between scc and nonsquamous histologies.
The role of histology was also assessed in a retrospective analysis of a phase iii trial of first-line vinorelbine-cisplatin compared with sb-paclitaxelcarboplatin and with gemcitabine-cisplatin 56 . No significant difference by histology was observed in the efficacy of these regimens; however, overall, a survival advantage was observed for patients with scc compared with those with adenocarcinoma (p = 0.0021). In the phase iii Global Lung Oncology Branch trial 3, patients with advanced nsclc were treated with first-line vinorelbine-cisplatin or with docetaxel-cisplatin 61 . In patients with scc, median os was 9.8 months in the docetaxel arm and 8.9 months in the vinorelbine arm; the respective orrs were 28% and 25%. Median os was similar between the arms for patients with adenocarcinoma (11.6 months vs. 11.7 months); the orr was 23% in the docetaxel arm and 29% in the vinorelbine arm.
In patients with scc, nab-paclitaxel-carboplatin demonstrated an orr of 41% compared with 24% for sb-paclitaxel-carboplatin (p < 0.001, Table iii) 12,62 . In patients with nonsquamous histology, nab-paclitaxel-carboplatin was as efficacious as sb-paclitaxelcarboplatin in terms of response (26% vs. 25%, p = ns), and compared with sb-paclitaxel-carboplatin, nab-paclitaxel-carboplatin also demonstrated a nonsignificantly higher orr in patients with large-cell carcinoma (33% vs. 15%, p = ns) and in those with undifferentiated histology (24% vs. 15%, p = ns). In both arms, patients with adenocarcinoma experienced a similar orr (26% vs. 27%, p = ns). activity and safety of nab-paclitaxel-carboplatin were also assessed in patients who were ineligible for bevacizumab (scc, history of thrombotic or embolic events or hemoptysis, or cavitary lung lesions) 64 . Results demonstrated an orr of 41% and a median os of 9.7 months in evaluable patients. The most common grades 3 and 4 toxicities were febrile neutropenia, infection, dyspnea, and dehydration. The molecular mechanism or mechanisms explaining the antitumour activity of nab-paclitaxelcarboplatin in patients with scc remain unknown; however, several hypotheses have been put forward. Many are focused on mechanisms that could lead to greater intratumoural paclitaxel accumulation. Compared with other tumour types, scc tumours occur in close proximity to major blood vessels, which might allow for greater access to the bloodstream 65 . Moreover, pharmacokinetic studies have demonstrated a higher systemic exposure to free paclitaxel in patients receiving nab-paclitaxel than in those receiving sb-paclitaxel, and thus more free paclitaxel might be available to scc tumours 48 . Nab-paclitaxel might avoid the limitations of sbpaclitaxel (entrapment of free paclitaxel in Kolliphor el micelles) because it is albumin-bound [46] [47] [48] . Furthermore, albumin crosses endothelial cells by cell surface receptor-mediated transcytosis 66 . In preclinical studies, nab-paclitaxel crossed endothelial cell layers more efficiently (by a factor of more than 4) than sb-paclitaxel did 49 . Synergy between nab-paclitaxel and other chemotherapy agents has been suggested; thus, it is also possible that nabpaclitaxel acts in synergy with carboplatin [67] [68] [69] .
First-line nab-paclitaxel-carboplatin in combination with bevacizumab has also been assessed in patients with advanced nonsquamous nsclc 70 . The orr was 31%, and the median os was 16.8 months. The most common grades 3 and 4 aes were neutropenia, fatigue, febrile neutropenia, thrombocytopenia, and neuropathy (with no grade 4 neuropathy being observed). Those results indicate that the nab-paclitaxel-carboplatin combination holds promise for the treatment of patients with advanced nonsquamous nsclc.
Nab-paclitaxel-carboplatin has demonstrated antitumour activity in patients with scc (for whom there is an unmet need) and in patients with nonsquamous histology in combination with bevacizumab. Future trials of nab-paclitaxel-carboplatin in combination with other targeted agents could reveal interesting findings in select patient populations.
Taxanes in the Elderly
The median age at diagnosis of lung cancer is approximately 70 years 1 . Unfortunately, many elderly patients are undertreated because of toxicity concerns, comorbidities, and poor performance status 3 . Elderly patients are often underrepresented in clinical trials, and their treatment options are limited for the mentioned reasons 3, 71 . With increasing emphasis on the identification of the appropriate treatment for elderly patients, many subanalyses have been performed. Single-agent and platinum-based therapies have a historical median os of 8-13 months in phase iii studies in elderly patients with nsclc 6,71-75 .
In a phase iii trial (ifct-0501), elderly patients (70-89 years of age) with advanced nsclc and a World Health Organization performance status of 0-2 were randomized to sb-paclitaxel-carboplatin or single-agent vinorelbine or gemcitabine 71 . The sbpaclitaxel-carboplatin combination demonstrated a median os of 10.3 months compared with 6.2 months for monotherapy (p < 0.0001). Grades 3 and 4 aes occurred more frequently in the platinum doublet arm and included neutropenia, anemia, febrile neutropenia, thrombocytopenia, asthenia, and anorexia. Despite the increased toxicity, the survival benefits lend support for the use of doublet therapy in elderly patients. In a subanalysis of the ecog 4599 trial, the addition of bevacizumab to sb-paclitaxel-carboplatin resulted in a greater orr in patients 70 years of age or older (29% vs. 17% with sb-paclitaxel-carboplatin alone, p = ns), but no improvement in median os (11.3 months vs. 12.1 months, p = ns) and a higher degree of toxicity 76 .
Elderly patients treated with docetaxel-cisplatin in the tax 326 trial had a median os of 12.6 months; the os in the vinorelbine-cisplatin arm was 9.9 months; it was 9.0 months in the docetaxel-carboplatin arm 72 . More elderly patients in the vinorelbine arm than in either docetaxel arm experienced grades 3 and 4 aes, and more grades 3 and 4 aes occurred with docetaxel-carboplatin than with docetaxel-cisplatin. Regardless of treatment, more neurotoxicity, pulmonary events, infection, anorexia, dehydration, and neuromotor issues were experienced by elderly patients in the study than by younger patients. In two phase ii trials of docetaxel-carboplatin in elderly patients (median age: 74-75 years), the median os ranged from 9.9 months to 13.1 months, and the orr was approximately 47% in both trials 77, 78 . Common grades 3 and 4 toxicities in both trials included neutropenia and anemia. Recent preliminary results from a phase iii trial of gemcitabine compared with docetaxel-gemcitabine in elderly patients revealed no significant differences in survival or response 79 .
Compared with sb-paclitaxel-carboplatin, nab-paclitaxel-carboplatin recently demonstrated improved outcomes in a subgroup of elderly patients (70 years of age and older) enrolled in a phase iii trial (Table iii) 12,63 , with a median os of 19.9 months compared with 10.4 months (p = 0.009). A higher orr was also observed in the elderly patients treated with nab-paclitaxel-carboplatin (34% vs. 24% with sb-paclitaxel-carboplatin, p = ns). Toxicities were similar in patients less than 70 and 70 or more years of age, and scores on the Functional Assessment of Cancer Therapy-Taxane instrument revealed significant treatment effects favouring nab-paclitaxelcarboplatin for neuropathy (p < 0.001), pain in hands and feet ( p < 0.001), edema ( p = 0.004), and hearing loss (p = 0.022).
The underlying mechanisms contributing to the antitumour activity of nab-paclitaxel-carboplatin in those elderly patients remain unknown. It is possible that the improvement in toxicity with nab-paclitaxel compared with sb-paclitaxel, particularly in neuropathy and neutropenia, might allow for higher dose delivery and intensity 12 . Treatment-related aes can affect patient quality of life and can lead to dose reductions and delays, which can affect treatment outcomes. In elderly patients with advanced nsclc, greater chemotherapy dose intensity was demonstrated to correlate with better survival outcomes 80 .
Finally, among elderly patients in the aforementioned phase iii trial, a greater percentage receiving nab-paclitaxel-carboplatin than receiving sbpaclitaxel-carboplatin went on to receive secondline therapy, which has been demonstrated to improve survival over best supportive care or placebo 63, 81, 82 . Further studies are warranted to determine the reasons for the improved os demonstrated by nab-paclitaxel-carboplatin in elderly patients.
CONCLUSIONS
The efficacy and safety profiles of taxanes have remained consistent over the years since their introduction. In patients with advanced nsclc, sbpaclitaxel-carboplatin has long been considered the cornerstone of first-line therapy. More recently, compared with sb-paclitaxel-carboplatin, nabpaclitaxel-carboplatin has demonstrated improved response rates, manageable toxicity, and statistically and clinically significant reductions in patient-reported 
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